Enterprise Value
29.85M
Cash
35.97M
Avg Qtr Burn
-7.91M
Short % of Float
1.19%
Insider Ownership
6.07%
Institutional Own.
12.13%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Zygel (ZYN002 CBD Gel) Details Genetic disorder, Rare genetic disease, Fragile X syndrome | Phase 3 Data readout | |
Zygel (ZYN002 CBD Gel) Details Genetic disorder, Rare genetic disease, Deletion Syndrome | Phase 3 Initiation | |
Zygel (ZYN002 CBD Gel) Details Epilepsy | Failed Discontinued | |
Zygel (ZYN002 CBD Gel) Details Autism spectrum disorders | Failed Discontinued |